title: A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression.
abstract: BACKGROUND
  We evaluated and compared the efficacy and safety of sertraline and fluvoxamine in a randomized, double-blind, parallel-group study during a follow-up of 24 months.
  
  
  METHODS
  Sixty-four patients with recurrent, unipolar depression (DSM-IV criteria) who had at least one depressive episode during the 18 months preceding the index episode were accepted into the trial. Patients were randomly assigned to one of the two long-term treatment groups and evaluated monthly by trained psychiatrists, blinded to treatment option, on the basis of the Hamilton Rating Scale for Depression.
  
  
  RESULTS
  All patients completed the 24-month follow-up period. Sertraline and fluvoxamine showed an equal efficacy in preventing new recurrences. In fact, there was no significant difference in survival rates between the two medication groups: 7 sertraline-treated patients (21.9%) and 6 fluvoxamine-treated patients (18.7%) had a single new recurrence (z = 0.14; p = .88). Moreover, recurrence observed during maintenance therapies was less severe and/or of shorter duration than index episodes.
  
  
  CONCLUSIONS
  Long-term treatment with sertraline or fluvoxamine has been shown to be effective for prevention of highly recurrent unipolar depression. The high tolerability of these compounds, together with their prophylactic effectiveness, has an important role in improving the quality of life of these patients.
authors.affiliation: Istituto Scientifico H. San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Franchini
authors.forename: M
authors.initials: M
authors.lastname: Gasperini
authors.forename: J
authors.initials: J
authors.lastname: Perez
authors.forename: E
authors.initials: E
authors.lastname: Smeraldi
authors.forename: R
authors.initials: R
authors.lastname: Zanardi
mesh_terms: D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000517:prevention & control* / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D016666:Fluvoxamine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D012008:Recurrence; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline; D016896:Treatment Outcome
chemical_list: D015057:1-Naphthylamine; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline